Roberto Adamo

Roberto Adamo obtained his PhD in Pharmaceutical Science from the University of Catania (Italy) in 2003, with a thesis on the synthesis of biologically relevant inositols. He was post-doctoral fellow at the NIH in Bethesda (USA), under the supervision of Dr. P. Kovac, and then in the group of Prof. J. P. Kamerling at the Utrecht University (The Netherlands). In 2007 he joined Novartis Vaccines where he was later apoointed Head of the Carbohydrate Chemistry Laboratory, and Leader of the...See more

Roberto Adamo obtained his PhD in Pharmaceutical Science from the University of Catania (Italy) in 2003, with a thesis on the synthesis of biologically relevant inositols. He was post-doctoral fellow at the NIH in Bethesda (USA), under the supervision of Dr. P. Kovac, and then in the group of Prof. J. P. Kamerling at the Utrecht University (The Netherlands). In 2007 he joined Novartis Vaccines where he was later apoointed Head of the Carbohydrate Chemistry Laboratory, and Leader of the Conjugation & Synthesis Platform. Following the company acquisition by GSK he became Preclinical Representative Leader of the Conjugation Platform. His research interests focus on the synthesis of glycans, glycoconjugates and glyconanoparticles to be used for carbohydrate-based therapeutics. He has been recently appointed Conjugation Technology Platform Leader at GSK, covering chemical and glycoengineering approaches for glycoconjugate vaccines. He is associate editor in the Glycoconjugate Journal and Coordinator of the EU network Glycovax. See less